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CHAPTER I 
 
INTRODUCTION 
 
iASPP is the inhibitory member of the ASPP family.  The ASPP family of proteins are 
named for both their structure (ankyrin repeats, SH3 domain, proline rich protein) and 
function (apoptosis stimulating protein of p53) (Ahn et al.2009; Robinson et al. 2008). 
Figure 1 illustrates the domains present in the ASPP family and their relative position in 
the ASPP protein family members. There are three members of the ASPP family: iASPP, 
which is anti-apoptotic, ASPP2, which is considered to be pro-apoptotic, and ASPP1, 
which has been shown to exhibit apoptotic effects in the nucleus while producing anti-
apoptotic effects when present in the cytoplasm (Vigneron et al. 2010; Bergnamaschi et 
al. 2003).  iASPP binds to and prevents p53 and p73 from transactivating their pro-
apoptotic targets while nuclear ASPP1 and ASPP2 bind to p53 and p73 and assist 
transactivation of target genes (Ahn et al. 2009; Robinson et al. 2008; Sullivan et al. 
2007). Despite their structural similarities (Figure 2), data suggest that iASPP and ASPP2 
bind to p53 at different sites (Ahn et al. 2009). ASPP2 binds to the core domain of p53; 
whereas, the evidence suggests that iASPP binds to the linker region of p53 (Ahn et al. 
2009). It has also been suggested that iASPP may bind to and inhibit the ASPP2-p53 
complex (Ahn et al. 2009). Specifically, it is the C-terminal region of iASPP that is 
responsible for its anti-apoptotic effects (Robinson et al. 2008; Ahn et al. 2009).  
However, it is unknown which residues of the p53 linker region are necessary for binding 
to iASPP. 
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Figure 1.  The domains of the ASPP protein family.  The C-termini of the three family 
members contain ankyrin repeats and an SH3 domain.  Likewise, they all share proline 
rich regions and glutamine rich regions.  However, it is only ASPP1 and ASPP2 that 
possess a ubiquitin like domain. Ahn et al. 2009. 
 
Figure 2. Structural similarity between ASPP family members.  The structure of iASPP 
(PDB ID 2VGE) is depicted in blue and ASPP2  (PDB ID 1YCS) is shown in orange.  
 
 
 3 
It is worth noting that the SH3 domain of ASPP2 contains the binding site for p53 which 
is slightly different than previously characterized SH3 domain/protein interactions. 
(Robinson et al. 2008; Ahn et al. 2009; Mayer 2001). In this case, it is not the proline rich 
region of p53 that binds to ASPP2 (Ahn et al. 2009).  However, there are some prolines 
present in the region of the p53 core domain that binds to the SH3 domain of ASPP2 
(Robinson et al. 2008; Gorina et al. 1997).  Recently, the crystal structure of ASPP2 
bound to p73 was reported which confirmed earlier NMR studies which indicated that 
ASPP2 binds the DNA binding domain of p73 (Ahn et al. 2009; Canning et al. 2012).  
The putative p53 binding site of iASPP is also composed of the SH3 domain of this 
ASPP family member, which has been shown to bind to the linker region of p53 rather 
than the proline rich region (Ahn et al. 2009).  However, the linker region of p53 
(residues 289-322) does contain four proline residues that are thought to be critical for 
binding to the SH3 domain of iASPP (Ahn et al. 2009).  These interactions are very 
important because the binding of iASPP to the tumor suppressors p53 and p73 results in 
the anti-apoptotic function of iASPP in cancer cells which suggests that iASPP may serve 
as a promising cancer target (Bergamaschi et al. 2003; Gillotin 2009; Bell et al. 2008). 
Indeed, iASPP can inhibit the tumor suppressors p53 and p73 that often prevent the 
formation of tumors and stop cells with mutated or damaged DNA from propagating.  
Proteins, such as iASPP, that inhibit tumor suppressors can lead to cancer cell 
proliferation when they are over expressed (Bergamaschi et al. 2003; Robinson et al. 
2008; Bell et al. 2008).   
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It has been shown that iASPP is over expressed in many cancer types, and silencing of 
this protein in cancer cell lines results in apoptosis or cell cycle arrest.  Over expression 
of  iASPP has been observed in leukemia, non-small cell lung cancer, ovarian cancer, 
glioblastoma, prostate, and liver cancers (Liu et al. 2009; Zhang et al. 2005; Jiang et al. 
2011; Chen et al. 2012; Li et al. 2012; Li et al. 2011; Zhang et al 2011; Lin et al. 2011; 
Deng et al. 2010).  In non-small cell lung cancer, iASPP over expression is associated 
with both metastasis and a decreased response to chemotherapy (Chen et al. 2010; Su et 
al. 2007).   Moreover, silencing of iASPP in leukemia, breast, glioblastoma, non-small 
cell lung cancer, ovarian, prostate, and liver cancer cell lines results in an increase in cell 
death (Chen et al. 2012; Li et al. 2011; Liu et al. 2009; Liu et al. 2008; Jiang et al. 2011; 
Lin et al. 2011).  Taken together, these studies suggest that iASPP may be a promising 
target for therapeutic inhibition for many cancer types. 
 
It is the role of iASPP in the p53 pathway (Figure 3) that makes iASPP so tantalizing as a 
target.  In response to oncogenic stress such as DNA breaks or the presence of lesions in 
DNA, p53 activates genes coding for pro-apoptotic and cell cycle arrest proteins 
including, but not limited to, Bax, PUMA, p21, DR5, and Fas, (Menendez et al. 2009). 
The up-regulation of these proteins leads to cell death or cell cycle arrest in cells 
experiencing oncogenic stress (Menendez et al. 2009; Sullivan et al. 2007).  There are 
also many co-factors that bind to p53 and promote the transactivation of specific p53 
targets (Harms et al. 2004; Sullivan et al. 2007).  ASPP1 and ASPP2 are among the 
cofactors than influence the ability of p53 to bind pro-apoptotic target genes (Bell et al. 
2007; Bell et al. 2008). iASPP, however, blocks the ability of p53 to transactivate its pro-
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apoptotic and pro-cell cycle arrest targets (Bell et al. 2007; Bergamaschi et al 2003; 
Robinson et al. 2008).  Thus, the tumor suppressor function of p53 is inhibited by iASPP 
allowing cancer cells to abberantly proliferate (Bergamaschi et al 2003; Bell et al 2007; 
Bell et al. 2008).  Removal of iASPP’s inhibition of p53 may restore the apoptotic or cell 
cycle arrest function of p53, thereby, leading to a reduction in the number of cancer cells.   
 
This hypothesis assumes that p53 is not mutated and is functional.  However, p53 is 
mutated or deleted in half of all human tumors (Hollstein et al. 1991).  In these cancers, 
iASPP could still function by binding to a related tumor suppressor protein, p73. p73, like 
p53, functions as a tumor suppressor by transactivating pro-apoptotic and cell cycle arrest 
genes in cells experiencing oncogenic stress (Bell et al. 2007). In fact, these two proteins 
share many of the same downstream pro-apoptotic and cell cycle arrest target genes (Bell 
et al. 2007).  
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Figure 3. Abbreviated p53/p73 pathway. p53 transactivates many target genes resulting in 
cell cycle arrest or apoptosis.  iASPP can inhibit both p53 and p73.   
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In support of this hypothesis, iASPP inhibition has been shown to lead to an increase in 
apoptosis via p73 (Bell et al. 2007). This data suggests that inhibiting iASPP may be a 
viable option as a cancer therapy in patients where iASPP is over expressed and p53 is 
non-functional.  This is supported by data on iASPP inhibition generated by the Ryan 
Lab which demonstrated that disruption of the iASPP-p73 interaction by a 37 amino acid 
peptide resulted in a dramatic reduction in tumor size  in a mouse xenograft model (Bell 
et al. 2007).  This 37 amino acid peptide (37-mer) was shown to disrupt the interaction 
between iASPP and p73 in cell lines and in vivo models (Bell et al. 2007).  By the 
disruption of this protein-protein interaction, the number of cancer cells was significantly 
reduced compared to non-transformed cells (Bell et al. 2007).  These data were the same 
for cancer cells containing p53 as well as cancer cells lacking functional p53 (Bell et al. 
2007).  Additionally, the down stream targets of p53 and p73 were induced upon iASPP 
inhibition (Bell et al. 2007).  These results further indicate that targeting iASPP may be 
an effective new strategy for treating many types of cancer, including cancers that lack 
functional p53.  
 
In order to determine if iASPP is a viable protein to target in the search for new cancer 
therapies, we needed to establish the following: 1) whether iASPP is druggable with a 
small molecule inhibitor 2) whether robust and efficient assays can be developed to 
functionally evaluate small molecules that bind to iASPP, and 3) whether we can verify 
and further validate iASPP as a potential cancer target through the use of RNAi.  For my 
thesis, I investigated the first two criteria, and while a fellow lab member, Bhavaratini 
Vangamudi, simultaneously investigated the third criterion.  
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To establish whether iASPP is a druggable protein target, we pursued a fragment-based 
approach where it has been shown that the hit rate obtained in a fragment-based screen is 
correlated to the druggability of the protein (Hajduk et al. 2007). Towards this end, 
iASPP was cloned, expressed, labeled, purified, and screened against our library of 
15,000 chemical fragments by NMR. In this case, we used a SOFAST-HMQC 
experiment to screen for chemical fragments that bind to 15N labeled iASPP C-terminus 
(Schanda et al. 2005).  Binding of fragments to iASPP causes measurable chemical shift 
changes of the amino acid residues perturbed by the binding.  These chemical shift 
changes allow identification of fragments that bind to iASPP (“hits”) (Shuker et al. 
1996). As a measure of druggability, a hit rate of 0.3% in a fragment-based screen results 
in the development of a small molecule inhibitor 80% of the time in the cases studied 
(Hajduk et al. 2007). In addition to being a useful indicator of protein druggability, these 
fragments serve as a starting point for the design of more potent inhibitors of iASPP 
(Hajduk et al. 2007; Shuker et al. 1996). Our goal was to compare the hit rate generated 
with iASPP to previously reported hit rates and obtain a measure of the druggability of 
iASPP; these date would guide us in determining whether or not we should pursue iASPP 
as a viable cancer target in our lab.  
 
In order to meet our second criteria, we sought to develop an FPA (fluorescence 
polarization anisotropy) assay in order to measure the disruption of the interaction 
between iASPP and peptides that bind to iASPP (Souza-Fagundes et al. 2012).  
Successful development of an assay that is reliable, reproducible, and efficient to measure 
the ability of a small molecule to disrupt this interaction is critical.  
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CHAPTER II   
 
PREPARATION OF iASPP FOR FRAGMENT-BASED SCREENING 
 
Introduction 
The first step toward conducting a fragment-based screen using NMR is to produce 
purified isotopically labeled protein in sufficient amounts to complete the screen.  
Preparation of the protein involves designing and testing different constructs, 
recombinant expression of our constructs for optimal protein expression levels, and 
optimizing the buffer conditions of the NMR sample to obtain the best NMR spectrum. 
 
Methods 
Each construct was expressed in electrocompetent E. coli strains BL21 Gold, BL21 RIL, 
Rosetta 2, and Rossetta 2 RIL for expression testing. The constructs were optimized for 
expression in M9 minimal media in small scale of 5 ml before optimizing expression of 
the protein in 1.5 liters of media in baffled flasks.  For expression testing, a series of 
experiments were performed for each construct and each E. coli strain.  For each, the 
protein was induced with IPTG (isopropyl ß-D-1-thiogalactopyranoside) at 37oC for 5 
hours, 25oC for 5 and 16-18 hours, or 18oC for 16-18 hours.  The culture was then 
centrifuged at 3,000 x g for 15 minutes and the supernatant was discarded.  The cell pellet 
was then re-suspended in phosphate buffer and sonicated at 4oC to lyse the cells.  The cell 
lysate was then centrifuged, and the supernatant was collected for SDS-PAGE analysis of 
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protein expression.  Protein expression was determined by the appearance of a band on 
the PAGE gel at the appropriate molecular weight where no band is present in the 
 un-induced samples.  For expression trials, the buffer contained 50 mM phosphate, 100 
mM NaCl, and 5 mM DTT.  Once expression was established, optimization of the 
purification of the protein was the next step.  All constructs had a 6-His tag for nickel 
column chromatography.  Unbound protein was washed from the nickel column with a 
minimum of four column volumes of buffer containing 20 mM imidazole before bound 
protein was eluted with a gradient of increasing imidazole concentrations from 20 mM to 
500 mM imidazole. For constructs with a TEV (tobacco etch virus) protease cleavage 
site, TEV protease was added and subtractive nickel column chromatography was 
performed.  For purification of the constructs without a TEV cleavage site, a size 
exclusion chromatography step was added.  In some cases, we also conducted ion 
exchange chromatography to obtain a more pure sample that was free of aggregates and 
impurities.   
 
Following the production of recombinantly expressed and purified iASPP, a two-
dimensional 1H/15N correlation spectrum was collected in those cases where a sufficient 
yield of the protein was obtained. We chose to perform a 1H/15N SOFAST-HMQC 
spectrum because SOFAST-HMQC has an advantage of shorter inter scan delays 
allowing more repetitions of the experiment in shorter time which results in a the signal 
to noise increase compared to the HMQC experiment. (Schanda et al. 2005).   
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Results 
Initially, we selected the iASPP C-terminal construct ∆623-828 because it contains the 
SH3 domain (the domain we wish to inhibit) and the ankyrin repeats. It is imperative to 
express the SH3 domain with the ankyrin repeats because the SH3 domain alone is not 
stable and does not express well. This particular construct was also reported by Ahn et al 
in their work. Thus, there is literature precedent for the recombinant expression of this 
construct. We cloned ∆623-828 into an expression vector containing an N-terminus His-
tag.  We expressed this construct in four strains of electrocompetent E. coli (BL21 Gold, 
BL21 RIL, Rosetta 2, and Rossetta 2 RIL). The level of expression was low for each 
strain.  We observed that protein expression levels were poor for protein expressed at 
37oC for 5 hours or 25oC for 16-18 hours. This level of expression (estimated at less than 
10 mg/L) was insufficient to generate enough protein to conduct the screen. However, 
when the protein was expressed at 18oC for 16-18 hours, sufficient protein was expressed 
to allow purification (40 mg/L).   
 
After obtaining purified protein, we collected spectra of iASPP in order to determine if 
our construct would be suitable for screening by NMR.  In order to determine if our 
construct was indeed suitable for conducting a fragment-based screen, which is 
conducted in mixtures of 12 fragments, we collected a SOFAST-HMQC spectrum of 
iASPP ∆623-608 in the presence (Figure 4) and absence of a fragment mixture. The 
spectrum of iASPP in Figure 4 with the fragment mixture clearly shows the protein is 
precipitating. The spectrum of iASPP alone was similar to the published spectrum of 
iASPP (Ahn et al. 2009). Furthermore, this construct was not stable at room temperature 
 12 
for more than a few hours.  For the screen, we must have protein that can withstand room 
temperature conditions for several hours in order to facilitate the efficient screening of 
our fragment library, and the protein must be stable when combined with our fragment 
mixtures. To test whether our purified protein was free from all aggregates, we extended 
our purification scheme to include size exclusion and anion exchange columns.  In 
addition, we tried to reduce the concentration of our fragment mixture in half (400 µM vs 
800 µM).  Unfortunately, we were unable to see any improvement in the quality of our 
NMR spectra.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 13 
 
Figure 4. SOFAST-HMQC spectrum of ∆623-828 iASPP with a fragment mixture. This 
spectrum demonstrates the poor quality of spectra that result from this construct of iASPP 
when fragments are present.   
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In order to conduct the fragment screen, it was imperative to improve the stability of the 
protein.  We experimented with varying salt conditions and buffers in an attempt to 
increase the stability.  Initially, we maintained a 50 mM phosphate buffer with 5 mM 
DTT while varying the type and concentrations of salt.  At a pH of 7.3, we tested our 
protein with 50 mM NaCl, 100 mM NaCl, 150 mM NaCl, 200 mM NaCl in 50 mM 
phosphate and 5 mM DTT.  None of these NaCl concentrations improved the stability of 
the protein.  In fact, at 50 mM NaCl, the protein visibly precipitated in the presence of the 
fragment mixture. We also tried KCl and MgCl2 with and without NaCl. NaCl was 
maintained at 100 mM to balance the stabilizing effect of the salt while varying the 
concentrations of KCl and MgCl2.  We tested many salt and buffer conditions including: 
1) 50 mM KCl, 100 mM NaCl, 50 mM PO4, 5 mM DTT 2) 100 mM KCl, 100 mM NaCl, 
50 mM PO4, 5 mM DTT 3) 150 mM KCl, 100 mM NaCl, 50 mM PO4, 5 mM DTT 4) 
200 mM KCl, 100 mM NaCl, 50 mM PO4, 5 mM DTT 5) 100 mM KCl, 50 mM PO4, 5 
mM DTT 6) 150 mM KCl, 50 mM PO4, 5 mM DTT 7) 200 mM KCl, 50 mM PO4, 5 mM 
DTT 8) 50 mM MgCl2, 100 mM NaCl, 50 mM PO4, 5 mM DTT 9) 50 mM MgCl2, 150 
mM NaCl, 50 mM PO4, 5 mM DTT 10) 150 mM MgCl2, 100 mM NaCl, 50 mM PO4, 5 
mM DTT 11) 50 mM MgCl2, 50 mM PO4, 5 mM DTT 12) 100 mM MgCl2, 50 mM PO4, 
5 mM DTT 13) 150 mM MgCl2, 50 mM PO4, 5 mM DTT 14) 200 mM MgCl2, 50 mM 
PO4, 5 mM DTT 15) 50 mM KCl, 50 mM MgCl2, 50 mM NaCl, 50 mM PO4, 5 mM DTT 
16) 50 mM KCl, 50 mM MgCl2, 50 mM PO4, 5 mM DTT 17) 50 mM KCl, 50 mM 
MgCl2, 50 mM PO4, 5 mM DTT 18) 50 mM KCl, 100 mM MgCl2, 50 mM PO4, 5 mM 
DTT 19) 50 mM KCl, 150 mM MgCl2, 50 mM PO4, 5 mM DTT 20) 100 mM NaCl, 50 
 15 
mM PO4, 5 mM DTT.  None of these conditions offered any improvement in the quality 
of the NMR spectrum of the protein. 
 
Next, we tried adding ammonium sulfate, which is known to have a stabilizing effect on 
proteins.  However, this salt can also precipitate or “salt out” a protein very quickly; thus, 
we used a total concentration of 25 mM in order to avoid salting out our protein while 
enhancing its stability. We tried the following: 1) 50 mM PO4, 100 mM NaCl, 25 mM 
NH2SO4, 5 mM DTT 2) 50 mM PO4, 150 mM NaCl, 25 mM NH2SO4, 5 mM DTT 3) 50 
mM PO4, 100 mM KCl, 25 mM NH2SO4, 5 mM DTT 4) 50 mM PO4, 100 mM NaCl, 100 
mM MgCl2, 25 mM NH2SO4, 5 mM DTT 5) 50 mM PO4, 150 mM KCl, 25 mM 
NH2SO4, 5 mM DTT 6) 50 mM PO4, 100 mM KCl, 100 mM MgCl2, 25 mM NH2SO4, 5 
mM DTT.  Once again, we were unable to note any improvement in protein stability.  
 
We also tried additional buffers, including HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid ), Tris-HCl (Tris(hydroxymethyl)aminomethane 
hydrochloride) , and MES (2-(N-morpholino) ethanesulfonic acid).  The buffer conditions 
tested include: 1) 50 mM Tris-HCl, 100 mM NaCl, 25 mM NH2SO4, 5 mM DTT 2) 50 
mM Tris-HCl, 100 mM NaCl, 5 mM DTT 3) 50 mM Tris-HCl, 100 mM NaCl, 100 mM 
MgCl2, 5 mM DTT 4) 50 mM Tris-HCl, 100 mM KCl, 100 mM MgCl2, 5 mM DTT 5) 
50 mM Tris-HCl, 50 mM NaCl, 25 mM NH2SO4, 5 mM DTT 6) 50 mM HEPES, 100 
mM NaCl, 25 mM NH2SO4, 5 mM DTT 7) 50 mM HEPES, 100 mM NaCl, 5 mM DTT 
8) 50 mM HEPES, 100 mM NaCl, 100 mM MgCl2, 5 mM DTT 9) 50 mM HEPES, 100 
mM KCl, 100 mM MgCl2, 5 mM DTT 10) 50 mM HEPES, 50 mM NaCl, 25 mM 
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NH2SO4, 5 mM DTT 11) 50 mM MES, 100 mM NaCl, 25 mM NH2SO4, 5 mM DTT 12) 
50 mM MES, 100 mM NaCl, 5 mM DTT 13) 50 mM MES, 100 mM NaCl, 100 mM 
MgCl2, 5 mM DTT 14) 50 mM MES, 100 mM KCl, 100 mM MgCl2, 5 mM DTT 15) 50 
mM MES, 50 mM NaCl, 25 mM NH2SO4, 5 mM DTT.  None of these buffer conditions 
made any improvement in the stability of our protein.   
 
The next logical parameter to optimize was the pH of the buffer solution.  The theoretical 
isoelectric point of iASPP C-terminus is 4.4. We, therefore, chose to experiment with pH 
in the range of 6.0-8.0 in order to balance the need for less basic pH in our NMR 
experiments with the low pI of the protein. We chose the following buffer conditions in 
which to vary the pH. They are as follows: 1) 50 mM PO4, 100 mM NaCl, 25 mM 
NH2SO4, 5 mM DTT 2) 50 mM PO4, 100 mM NaCl, 5 mM DTT 3) 50 mM Tris-HCl, 
100 mM NaCl, 5 mM DTT 4) 50 mM MgCl2, 100 mM NaCl, 50 mM PO4, 5 mM DTT 5) 
50 mM MgCl2, 100 mM NaCl, 50 mM Tris-HCl, 5 mM DTT.  For each of the conditions 
listed above, we then varied the pH. We tested the stability of the protein at pH 6.5, 7.0, 
7.3, 7.5, 7.7, and 8.0.  Creating a more acidic buffer condition of 6.5 worsened the 
apparent stability of the protein; no improvement or difference was observed in the 
spectrum compared to those collected at pH 7.3- 8.0.  
 
Another possible reason for the poor quality NMR spectrum may have been our choice of 
reducing agent. While DTT is a common and effective reducing agent, it is more volatile 
than TCEP (tris(2-carboxyethyl)phosphine).  Thus, we chose to experiment with TCEP as 
a reducing agent in our buffer system.  However, TCEP is not very stable in phosphate 
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buffers near pH 7; therefore, we tested TCEP in Tris-HCl buffers in the following 
conditions: 1) 50 mM MgCl2, 100 mM NaCl, 50 mM Tris-HCl, 1 mM TCEP 2) 100 mM 
NaCl, 50 mM Tris-HCl, 1 mM TCEP 3) 50 mM Tris-HCl, 100 mM NaCl, 25 mM 
NH2SO4, 1 mM TCEP.  Although no improvement in the spectrum was observed, we 
continued to use TCEP as our reducing agent because of its potency and because it is 
more stable over time in open solutions which would be more ideal for screening 
conditions.  
 
Finally, we tested additives in order to improve the stability of our protein. The following 
conditions were tested: 1) 100 mM NaCl, 50 mM Tris-HCl, 1 mM TCEP, Ph 7.3 2) 50 
mM Tris-HCl, 100 mM NaCl, 25 mM NH2SO4, 1 mM TCEP, pH 7.3 3) 50 mM MgCl2, 
100 mM NaCl, 50 mM Tris-HCl, 1 mM TCEP, pH 7.3.  Into each of these buffers, we 
added 1% glycerol, 2% glycerol, or 5% glycerol.  Once again, we were unable to improve 
upon the stability of our protein.  Because the C-terminus of iASPP does contain free 
cysteines, we chose to test whether the addition of iodoacetic acid might improve the 
stability, but no improvement was obtained.   
 
Since all of our attempts to improve the stability of the protein and quality of the NMR 
spectra by altering the buffer conditions was not successful, we decided to test different 
constructs.  For example, MBP (maltose binding protein) was added to the His-tag on the 
N-terminus of our construct.  MBP is a popular chaperone protein capable of enhancing 
the folding and solubility of proteins during expression.  We reasoned that our protein 
might benefit from such a chaperone protein. The buffer conditions used to test our new 
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construct included: 1) 100 mM NaCl, 50 mM Tris-HCl, 1 mM TCEP, pH 7.3 2) 50 mM 
Tris-HCl, 100 mM NaCl, 25 mM NH2SO4, 1 mM TCEP, pH 7.3 3) 50 mM MgCl2, 100 
mM NaCl, 50 mM Tris-HCl, 1 mM TCEP, pH 7.3. No improvement was observed. 
Therefore, we moved the His-tag to the C-terminus of our construct and tested the protein 
using the same three buffer conditions listed above.  Once again, we saw no improvement 
in the ability of our protein to remain soluble or stable in our fragment mixtures.  
 
Therefore, we abandoned our ∆623-828 construct altogether and selected four additional 
constructs for testing.  In the first new construct, we mutated the free cysteines and 
created a C699S, C703S mutated form of ∆623-828. The second new construct  
(∆608-828) was chosen because it was used to determine the crystal structure of iASPP 
(Robinson et al).  The third new construct (∆625-828) was chosen due to a report in the 
literature on the successful expression of iASPP (Robinson et al) The fourth construct, 
(∆618-828) was chosen based on a secondary structure prediction of the C-terminus of 
iASPP in which a helix exists C-terminal to the first ankyrin repeat. This slightly longer 
construct (+5 residues) was selected to ensure that we were not truncating the protein in 
the middle of a helix. Despite many attempts to optimize the expression of constructs  
iASPP C699S and C703S,  ∆623-828, iASPP ∆618-828, and iASPP ∆625-828 using 
many conditions, we were only able to express very small amounts of protein.  In 
contrast, iASPP ∆608-828 overexpressed at 18oC overnight and was stable in 100 mM 
NaCl, 50 mM Tris-HCl, 1 mM TCEP, pH 7.3.  Therefore, we tested the stability of the 
protein upon the addition of a fragment mixture and were pleased with the quality of the 
NMR spectrum (Figure 5). In order to verify that this protein binds to relevant binding 
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partners, we collected spectra of iASPP∆608-828 in the presence and absence of the two 
peptides: a p53 linker region and GSPRKARRA. (Figure 6 and Figure 7).  iASPP C-
terminus has been shown to bind to the p53 linker region and to GSPRKARRA (an 
iASPP derived peptide) (Ahn et al. 2009, Robinson et al. 2007). The chemical shift 
changes observed suggest that iASPP ∆608-828 may be a functional protein.  Moreover, 
based on the expression levels obtained, and the stability of the protein in the absence and 
presence of fragment mixtures, we concluded that we had finally obtained a suitable 
construct and experimental conditions to conduct our fragment-based screening of iASPP 
by NMR. 
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Figure 5. SOFAST-HMQC of iASPP ∆608-825 iASPP collected at 293K on 500 MHz 
NMR spectrometer with fragment mixture.  This condition is stable for screening.  
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Figure 6. SOFAST-HMQC spectra of iASPP ∆608-828 bound to GSPRKARRA (blue) 
and free iASPP ∆608-828 (red). SOFAST-HMQC collected at 293K on 500 MHz NMR 
spectrometer.  
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Figure 7. iASPP ∆608-828 bound to p53 linker region (blue) and free iASPP ∆608-828 
(red). SOFAST-HMQC collected at 293K on 500 MHz NMR spectrometer. 
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CHAPER III 
 
FRAGMENT-BASED SCREEN 
 
Introduction 
In order to determine whether iASPP is a druggable target, we conducted a fragment-
based screen using NMR. This has been shown to be a useful approach to determine 
whether a particular protein is druggable.  Based on an earlier publication by Hajduk et 
al., a protein is likely druggable if the percentage of fragments that bind to the protein 
target is greater than 0.3% (Hajduk et al. 2007).  In that study, 58 protein targets that 
were the subject of fragment-based drug design efforts were used.  For protein targets 
where the hit rate was less than 0.1%, potent small molecule inhibitors were developed in 
only 3.2% of cases.  For protein targets with a hit rate of 0.1-0.3%, a potent small 
molecule inhibitor was developed in 31% of these cases, and, encouragingly, for hit rates 
exceeding 0.3%, potent small molecule inhibitors were developed in 82% of the targets 
studied (Hajduk et al. 2007).  In addition to being a valuable tool to investigate whether a 
protein target is druggable, fragment-based screens are a proven method for identifying 
fragments that can become the initial chemical matter needed to develop potent small 
molecule inhibitors.   
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Experimental Design 
iASPP residues 608-828 were recombinantly expressed and uniformly isotopically 
labeled with 15N as described in chapter 2.  Once sufficient quantities were obtained, 
iASPP was screened against our fragment library containing 15,000 compounds. Figure 8 
outlines the experimental approach for conducting the screen. To reduce the number of 
NMR spectra that we needed to collect as well as the amount of protein required to 
complete the screen, we screened the fragment library in mixtures containing 12 
compounds.  Chemical shift changes observed upon the addition of compound mixtures, 
indicated that one or more compounds in the mixture was binding to iASPP. A score of 
1-5, based on the magnitude of the observed chemical shift changes, was assigned to each 
mixture.  A score of 5 indicates a chemical shift change of about 0.5 ppm or greater; 
whereas, a score of 3 indicates a chemical shift change of about 0.25 ppm.  Mixtures with 
a score of 3 or higher were selected for de-convolution of the mixture in order to 
determine which fragment(s) was binding to iASPP. It is important to note that our 
scoring system does not imply a direct correlation with binding affinity because some 
compounds can induce a larger chemical shift change with lower affinity (e.g. 
compounds containing an aromatic ring).  Once individual fragments have been 
identified, titrations were performed in order to determine their binding affinity. Once 
this is complete, we selected analogs of the fragments identified and screened these 
individually.  
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Figure 8.  NMR fragment-based screen to identify fragments that bind to iASPP 
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In choosing how best to screen iASPP against our fragment library by NMR, we had to 
select which experiment would give us the most information in the most efficient way 
possible.  We considered both HSQC (heteronuclear single quantum coherence) and 
SOFAST-HMQC (selective optimized flip angle short transient - heteronuclear multiple 
quantum coherence) experiments.  TROSY-HSQC (transverse relaxation optimized 
spectroscopy - heteronuclear single quantum coherence) spectra of deuterated iASPP 
collected on a 900 MHz magnet have been previously reported by Ahn et al.  However, 
for conducting this type of screen, we must obtain the best possible spectra on a 500 MHz 
or 600 MHz magnet because these NMR spectrometers have a sample changer and we 
did not want to incur the expense of deuterating the protein. SOFAST-HMQC has the 
advantage of allowing shorter inter scan delays and more repetitions of the experiment in 
a shorter time, using this experiment, the signal to noise is increased compared to 
HMQC.  Before we were able to begin our screen, we optimized the protein 
concentration and optimized the parameters of the SOFAST-HMQC experiment to obtain 
the best signal to noise possible.  
 
Method 
iASPP was recombinantly expressed and isotopically labeled as described in chapter2. In 
order to determine the concentration of iASPP to be used in our NMR experiments, we 
collected spectra at 40 µM, 50 µM, 75 µM, 100 µM, 150 µM iASPP.  As expected,  
150 µM iASPP resulted in a stronger signal.  However, we discovered that 50 µM iASPP 
resulted in a sufficient signal and spectra for screening purposes.  This  finding is an 
advantage given that the screen requires a large amount of protein to complete, and each 
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batch of protein must be prepared freshly as iASPP becomes unstable during the freeze-
thaw process. For the fragment-based screen, iASPP was concentrated to a final 
concentration of 50 µM in 50 mM Tris-HCl, 100 mM NaCl, 1 mM TCEP, and 5 % 
deteurated DMSO.  Fragment mixtures of 12 were added to each sample of iASPP with a 
final concentration of either 400 µM or 800 µM for each fragment. SOFAST-HMQC 
NMR experiments were conducted on a Bruker 500 MHz or 600 MHz NMR 
spectrometer at 293K. Spectral analysis was conducted using TopSpin software.  Spectra 
from the fragment mixtures were overlaid with a spectrum of free iASPP.  For any 
spectrum in which we observed chemical shift pertubations relative to the reference 
spectrum, we identified a fragment hit. We then de-convolved the 12 individual 
fragments for the mixtures that contained these fragment hits.  By de-convolving the 
mixtures, we are able to identify those individual fragments that bind to iASPP.  We then 
determined the binding affinities of the fragments by performing NMR titration 
experiments.  For each titration experiment, the fragment was added to 50 µM iASPP at 
final concentrations of 800 µM, 600 µM, 400 µM, 200 µM, 100 µM, 50 µM and 25 µM.  
The magnitude of the change in chemical shift was measured and plotted against the 
concentration of fragment.  From this plot, we extrapolated the binding affinity (Kd) of 
the fragment.  
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Results 
The spectra in Figure 9 illustrate an example of the 1H/15N chemical shift changes 
observed upon the addition of one of our fragment hits. Upon binding to the p53 linker 
region, iASPP exhibits chemical shift changes at W798 and W800.  For most of our 
fragment hits, we also observe a chemical shift pertubation at W798 and/or W800. 
 
 
Figure 9.  A fragment identified as binding to iASPP.  A chemical shift pertubation is 
observed at W798, one of the W residues that experiences a chemical shift change when 
p53 binds to iASPP.  SOFAST-HMQC, 600 MHz, 293K, 50 µM iASPP. The 
assignments shown in this figure were reported by Ahn et al.  
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From our fragment mixtures, we identified two mixtures with a score of 5, indicating a 
rather large difference in the chemical shifts of unbound iASPP and iASPP bound to 
fragments.  We discovered five mixtures with scores of 4 and thirty-seven mixtures with 
scores of 3.  There were 71 mixtures with a score of 2 and 198 mixtures with a score of 1.  
We chose to de-convolute mixtures with scores of 3 or greater.  Our hit rate from scores 
of 2 or greater is 0.8%.  This indicates that iASPP is likely to be a druggable protein 
target.  
 
We characterized the fragments by their chemical class and begin to discern some of the 
structure activity relationships of these fragments. The diazapane class is outlined in 
Table 1.  It is interesting to note that the addition of a chlorine to the pyridyl group 
increases the affinity of the fragment to iASPP by an order of magnitude compared to the 
pyridyl-diazapane with a methyl side group.  Following the discovery of the diazapanes, 
we measured the binding of azapane compounds which are similar in structure; none of 
our azapane compounds bound to iASPP.  Substitution of the pyridyl group for either a 
benzyl or ethylamine group and a oxygen at the 2 position on the diazapane ring either 
further reduces the affinity of the fragment for iASPP or renders the compound unable to 
bind to iASPP.   
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Table 1. Diazapane fragments and approximate binding affinities 
 
 
 
Kd = 309 µM 
 
 
 
Kd = 2.64 mM 
 
Kd = 3.55 mM 
 
No binding 
 
No binding  
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Another class of compounds that we discovered bind to iASPP is the quinoline series 
shown in Table 2 and Table 3.  For 2-ring compounds in the quinoline series possessing 
an amine group at the carbon 2 position and methyl groups at the carbon 5 and 7 position, 
adding a methyl at carbon 6 gives a slight increase in affinity.  However, placing a flouro- 
at carbon 6 and either a hydroxyl or amine group at carbon 4 diminishes the binding 
affinity for quinolines to iASPP. Table 3 is a continuation of our investigation of the 
quinoline series of fragments that further illuminates which fragments might be best 
suited as the starting material for any potential small molecule inhibitor of iASPP.  
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Table 2. Quinoline fragments with 2-ring structure approximate Kd values. 
 
 
Kd = 650 µM 
 
 
Kd = 570 µM 
 
 
Kd = 1.64 mM 
 
 
 
Kd = 2.27 mM 
 
 
No binding 
 
 
No binding 
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Table 3 outlines the results from our continued study of the quinoline series as we expand 
into quinolines with a 3-ring structure.  Adding a benzyl to the quinoline structure where 
two methyl groups and an amino side group are already present, significantly increases 
the affinity of these fragments to iASPP.  Removing the ethyl and methyl groups from 
this structure results in a large decrease in affinity.  Removal of all but the amine side 
group also drastically decreases affinity.  The addition of a pyrrolidone or furan in place 
of the benzyl group on the quinoline structure decreases or completely obliterates the 
ability of the fragment to bind to iASPP.  This insight reveals that some members of the 
quinoline series are good candidates for becoming initial chemical matter in a small 
molecule inhibitor while the negative data in the series indicates where the specificity lies 
in these fragments.   
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Table 3. Quinoline fragments with a 3-ring structure and approximate Kd values.  
 
 
Kd =  110 µM 
 
 
Kd =  370 µM 
 
 
Kd = 1.89 mM 
 
 
 
Kd = 1.59 mM 
 
 
No binding 
 
 
A third series, amino-benzimidazole series, was also discovered. Table 4 is a summary of 
these fragments that we investigated as potential ligands to iASPP.  Two of these 
fragments are observed as having micromolar binding affinities and may be suitable to 
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develop further into a small molecule inhibitor.  It is clear, however, that adding benzyl 
or hydroxyl groups decreases the affinity four or five fold.   
 
Table 4. Amino-benzimidazole series and approximate binding affinities.  
 
 
Kd =  420 µM 
  
 
Kd = 660 µM 
 
 
Kd = 2.05 mM 
 
  
 
Kd = 2.80 mM 
 
Once we had obtained the data for the amino-benzo-imidazole class of compounds listed 
above, we then obtained compounds with similar structures as shown in Table 5. 
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Table 5. Compounds with similar structure to the amino-benzoimidazole compounds 
 
               
 
Kd = 3.77 mM 
                
Kd = 554 µM 
 
                
 
 
Kd = 827 µM 
              
Kd = 1.27 mM 
 
 
No binding 
 
No binding 
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No binding 
 
No binding  
 
No binding 
 
No Binding 
 
No binding 
 
No binding  
 
No binding 
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When the amine group at the 2 position is replaced with a thiol group, affinity is 
completely lost compared to the same 2-amino-benzimidazole with a hydroxyl ethyl 
group at the 1 position. We also see that when an amine is added to the benzene ring of 
the benzimidazole and the amine at the 2 position is replaced with a methyl group that 
affinity is lost completely. In general, the addition of fluorine and sulfur groups results in 
a complete loss of binding. While incorporating oxygen into the ring structure also results 
in a complete loss of binding.  However, we are able to narrow this class of compounds 
down to a few that are below 1 mM in affinity and have the potential to become the initial 
chemical matter from which a small molecule inhibitor could be designed.   
 
In order to complete this work, over 1,500 NMR experiments were performed and 
analyzed. We identified a hit rate for iASPP of approximately 0.9% indicating that it is 
likely possible to build a small molecule inhibitor to iASPP from the initial chemical 
matter identified in a second site screen. Thus, we are able to conclude that iASPP is a 
druggable target.  We were also able to establish a few types of fragments that share 
similar chemical structures and were able to determine, to a degree, which components of 
these fragments are important for binding and increasing affinity to iASPP.  Thus, we 
have also established a number of fragments with the potential to be further developed 
into a small molecule inhibitor of iASPP.   
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CHAPTER IV 
 
ASSAY DEVELOPMENT 
 
Introduction 
For drug discovery, it is imperative that robust assays can be developed in order to follow 
the SAR (structure activity relationship) of any chemical compounds that inhibit the 
target protein.  These assays are critical to any program designed to investigate a drug 
target and to all drug discovery programs. Thus, as part of my studies, I attempted to 
develop assays to characterize the compounds that bind to iASPP.  These involve assays 
that measure the ability of compounds to disrupt iASPP from binding to peptides in the 
putative p53 binding site using a FPA (fluorescence polarization anisotropy) assay.  
 
Experimental Design 
We pursued the development of an FPA assay to evaluate small molecule inhibitors of 
iASPP.  The principle of this assay (Figure 10) is that we are able to distinguish between 
labeled peptides bound to iASPP and labeled peptides that are unbound in solution with 
iASPP. Using this method, anisotropy increases as the binding of fluorophore labeled 
peptide to protein increases. The polarized light is measured, and anisotropy ( r ) can then 
be calculated by the formula: r = I|| - I⊥ / I|| + 2I⊥ (Rossi et al. 2011; Souza-Fagundes et al. 
2012). I|| equals the intensity of light detected that is parallel to the plane of polarization 
of light used to excite the fluorophore.  I⊥ represents the intensity of light emitted in the 
plane perpendicular to the plane of exciting light introduced to the system (Rossi et al. 
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2011; Souza-Fagundes et al. 2012). The disruption of the FITC-labeled peptide from 
binding to iASPP results in a change in the amount of polarized light emitted from the 
system. This assay can be performed in a 96-well or 384-well format and is read on the 
Envision Multi-label plate reader (Perkin Elmer) (Rossi et al. 2011; Souza-Fagundes et 
al. 2012). 
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Polarized Light Excites FITC 
  
 
 
 
 
 
 
 
 
Figure 10. FPA Assay.  Green star represents FITC excited by polarized light.  The 
emitted light passed through filters that are parallel and perpendicular to the plane of 
exciting light.  The intensity of light detected in the planes perpendicular and parallel to 
the exciting light are used to calculate anisotropy.   
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 Method 
Peptides derived from p53 were obtained commercially with and without a FITC probe at 
the N-terminus.  Peptides were re-suspended in water or buffer consisting of 50 mM Tris-
HCl, 100 mM  NaCl, and 1 mM TCEP or 5 mM BME and stored in aliquots at -20oC.  
Once aliquots were removed from -20oC, they were diluted to the working concentration 
of 312 nM and stored at 4oC for up to 48 hours. Several buffer conditions were tested 
including different concentrations of detergents (Tween 20, NP-40, Triton X) and various 
salts (100 mM NaCl to 200 NaCl and 100 mM MgCl2). The optimal concentration of 
FITC labeled peptide was examined by testing from 12.5 nM to 250 nM.  The final 
concentration of FITC labeled 9-mer used was 50 nM. Flat bottom black Nunc plates 
were used for this assay.  After the addition of the FITC labeled 9-mer and iASPP, the 
plate was centrifuged at 1,000 x g for 45 seconds and then rocked at room temperature 
for 20 minutes prior to reading.  The Envision plate reader was used to detect the 
fluorescence.  The raw data was maintained in Excel spreadsheets, and binding affinity 
calculations and graphs were produced using the Prism software.   
 
Results 
Ideally, the peptides to use for this assay would be derived from an endogenous and 
biologically relevant binding partner of iASPP.  The p53 linker region of iASPP is 34 
amino acids in length and has been previously reported to bind to iASPP with an affinity 
of 16 µM (Ahn et al).  Because one of our goals is to disrupt the p53-iASPP interaction, 
the linker region of p53 was used as a starting point for our peptide design.  Since, the 34 
amino acid p53 linker region is relatively long and could reduce our signal window in 
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this assay, and is more expensive than shorter peptides we tested seven shorter peptides 
for use in the FPA assay (Table 6). In addition to the 9 -mer (GSPRKARRA) that has 
been previously described (Ahn et al, Robinson et al), we designed and tested six 
additional peptides derived from the p53 linker region. The peptides were designed by 
first investigating whether the affinity of the p53 linker region was due to either the C- or 
N-terminus or combinations of the central portion of the peptide.  We discovered that 
both the C-terminus (peptide 2) and the N-terminus (peptide 3) of the p53 linker region 
have very low affinity for iASPP (Table 6).  We also tested the middle region of the p53 
(peptides 4-6). For two of the centrally located peptide sequences, we added an arginine 
residue to either terminus because the 9 -mer as well as the p53 linker region contains a 
high percentage of arginines and SH3 domains commonly bind to arginine residues. 
Unfortunately, many of these constructs abrogated binding of the peptides. The only 
peptides that were found to bind to iASPP were the previously observed 9 -mer (peptide 
8), the p53 linker region (peptide 1) and the middle 18 amino acids of the p53 linker 
region (peptide 7). This is not surprising given that most SH3 domains bind to peptides 
and proteins containing prolines.   
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Table 6. Peptide Sequences Investigated for use in FPA assay. * Indicates a binding 
affinity established by Ahn et al.  
Peptide 
# Peptide Sequence Kd Origin 
1 LRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKP 16 µM* 
p53 linker 
 
2                                GSTKRALPNNTSSSPQPKKKP > 400 mM 
p53 linker 
C-
terminus 
        3 LRKKGEPHHELPPGSTKRAL > 400 mM 
p53 linker 
N-
terminus 
4 GSTKRALP > 400 mM 
p53 linker 
middle 
8 mer 
5 GSTKRALPR > 400 mM 
p53 linker 
middle 8-
mer + R 
       6                                  RSTKRALP > 400 mM 
p53 linker 
middle 8-
mer -G + 
R 
       7              EPHHELPPGSTKRALPNN 27 µM 
p53 linker 
middle 
18 mer 
      8 GSPRKARRA 25 µM 
iASPP 9-
mer 
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Given these binding affinities, we chose to pursue development of the FPA assay using 
the p53 linker region (peptide 1) and the 9 -mer (peptide 8).  As a first step, we ordered 
both peptides with an N-terminal FITC moiety. We performed NMR titrations on the 
FITC -labeled peptides to confirm binding of the modified peptides and to determine the 
binding affinity.  Surprisingly, the affinity of the p53 linker region for iASPP was 
drastically reduced (Kd = 510 µM) upon addition of the FITC label.  We concluded that 
the FITC probe is interfering with binding of the peptide to the protein and is therefore 
unsuitable for use in this assay. 
 
Therefore, we pursued the development of the FPA assay with the 9 -mer.  Determination 
of the binding affinity of the 9 -mer with and without the FITC label by NMR confirmed 
the affinity of the labeled peptide (Figure 11).   
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Figure 11. SOFAST-HMQC titration of 9 -mer labeled with FITC and unlabeled. 50 µM 
iASPP in 50 mM Tris-HCl, 100 mM NaCl, 1 mM TCEP, pH 7.3.  
 
Next, we determined the binding affinity of the FITC -labeled 9 -mer by our FPA assay 
as shown in Figure 12.   
 
 
 
 
 
 
 
 
Figure 12.  FPA assay iASPP titration for Kd determination. Kd ~ 41 µM 
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The difference between the binding affinity of the FITC labeled 9 -mer determined by 
NMR and by the FPA assay is approximately four fold. Additionally, the binding curve 
derived from the FPA assay does not plateau and exhibits a linear shape, suggesting this 
assay is not performing properly. One possible explanation for the observed results could 
be non-specific binding or aggregation of the peptide.  Therefore, we attempted to 
optimize our assay conditions.  
 
First, we added 1% and 5% DMSO to the FPA assay; this is only difference in conditions 
between the NMR and FPA assay conditions.  However, we saw no improvement of 
either the binding affinity or of the curve shape upon addition DMSO.  Next, we tested 
different buffer conditions using detergents and salt which can alleviate non-specific 
interactions.  Our initial buffer conditions were 50 mM Tris-HCl, 100 mM NaCl, 1 mM 
TCEP, pH 7.3.  We added detergents at varying concentrations to this buffer including: 1) 
Tween 20 0.05% 2) Tween 20 0.1% 3) NP-40 0.5% 4) NP-40 0.1% 5) Triton X 0.05% 6) 
Triton X 0.1%.  Then, we experimented with added salt, including: 1) 50 mM MgCl2 2) 
100 mM MgCl2 3) 200 mM NaCl 4) 50 mM MgCl2 and Tween 20 0.05% 5) 50 mM 
MgCl2 and Tween 20 0.1% 6) 50 mM MgCl2 and NP-40 0.05% 7) 50 mM MgCl2 and 
NP-40 0.1% 8) 50 mM MgCl2 Triton X 0.05% 9) 50 mM MgCl2 Triton X 0.1%.  Figure 
13 below shows two of these results.  The addition of detergents and salts did not 
ameliorate the non-specific binding that is adversely affecting our assay.  
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Figure 13.  FPA assay binding curve of iASPP and FITC-labeled 9-mer.  
 
 
Next, we considered whether the unlabeled 9 -mer would be able to compete off the FITC 
labeled 9 -mer.  This is an important control because it demonstrates that the binding of 
the FITC labeled 9 -mer to iASPP is not due to the FITC probe (Figure 14).   
 
 
 
 
 
 
 
 
Figure 14.  The unlabeled 9 -mer competes off FITC labeled 9 -mer.   
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Taken together with the results from our NMR binding studies of the 9 -mer with and 
without the FITC probe, we conclude that the 9 -mer is binding to our iASPP construct in 
a manner that is peptide and not FITC probe dependent.   
 
Upon further inspection of the raw data from Figure 12 and repeats (data of repeats not 
shown), it became apparent that the total fluorescence is decreasing as a function of 
protein concentration (Figure 15).  This is an unexpected result because the total 
fluorescence should remain the same when the concentration of fluorophore is the same.   
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Figure 15.  Total flourescence as a function of iASPP concentration in FPA assay.  Total 
FITC –labeled peptide concentration is constant at 50 nM in all samples.  
 
We hypothesized that binding of the FITC-labeled peptide to iASPP may be responsible 
for decreasing the total fluorescence. iASPP contains tryptophan residues which are 
fluorescent and are observed to have an excitation wavelength of 280 nM and an 
emission wavelength of 348 nM while FITC has an observed absorption wavelength of 
495 nM and an emission wavelength of 521 nM.  Therefore, it is unlikely that the 
tryptophan residues are causing the quenching of the FITC probe.  If the FITC was 
quenching upon binding of the peptide to iASPP, we would expect to see this reversal of 
this effect when the unlabeled 9-mer competes off.  However, this was not observed 
(Figure 16).  Therefore, in this case, it seems that FITC should not be used as a 
fluorescent probe in this assay.  Our recommendation to improve this assay would be to 
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use another fluorescent probe attached to the 9-mer.  There are several other fluorescent 
probes available that would be suitable for this assay including rhodamine derivatives and 
fluorescein derivatives other than FITC.  
 
 
 
Figure 16.  Average total fluorescence values for FP assay where unlabeled 9-mer off-
competes the FITC labeled 9-mer. Each concentration of iASPP was measured in 
triplicate samples. The blue bars indicate the total fluorescence and the red bars indicate 
the difference between total fluorescence in the FITC only sample when compared to 
samples containing iASPP.   
 
Alternatively, it may be necessary to develop a different type of assay. One possibility  is 
an ELISA (enzyme linked immunosorbent assay) to observe the disruption of the iASPP-
peptide interaction or the iASPP-p53 interaction using full length proteins.  
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CHAPTER V 
 
SUMMARY 
 
The current literature on iASPP suggests that iASPP may be a potential new target for 
cancer therapy, especially, since iASPP inhibition could potentially initiate apoptosis via 
p53 or p73 pathways (Bell et al. 2007; Bergamaschi et al. 2003).  This is an important 
advantage because p53 is mutated or deleted in over half of all human tumors (Harms et 
al. 2004).  It is possible to activate apoptosis through p73, which is a part of the p53 
family of tumor suppressors and shares many of the same pro-apoptotic targets with p53 
(Bell at al. 2007; Bell et al 2008). This makes iASPP an appealing target because we may 
have the potential to affect apoptosis through not one, but two tumor suppressors in a 
wide variety of cancers. In addition to inhibiting apoptosis through both p53 and p73, 
iASPP is over-expressed in several cancer types and is associated with poor response to 
chemotherapy and metastasis (Liu et al. 2009; Zhang et al. 2005; Jiang et al. 2011; Chen 
et al. 2012; Li et al. 2011; Lin et al. 2011). Thus far, the reported data on iASPP show 
that silencing of iASPP in cancer lines and xenograft models is able to reduce 
proliferation of cancer cells and reduce tumor size (Bell et al. 2007).  In addition, studies 
conducted with a 37 amino acid peptide has shown that disrupting the interaction 
between p73 and iASPP results in p73- dependent apoptosis in cancer lines with no effect 
on non-transformed cell lines (Bell et al; 2007).   
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Because of the apparent function of iASPP in inhibiting apoptosis in many cancer types, 
we chose to investigate whether iASPP would represent a valuable cancer target.  In 
order to evaluate iASPP as a cancer target, we tested whether it could be druggable with 
small molecules, whether we could develop biological assays to test binding, and whether 
we could further validate iASPP as a target in our hands using siRNA. 
 
Once we were able to determine how to prepare enough protein to conduct a fragment-
based screen using NMR and optimized the screening conditions, we screened our 
fragment library containing 15,000 compounds. Several of these small molecules were 
found to bind to iASPP (hit rate = 0.8%).  These results suggest that iASPP is likely to be 
a druggable protein.  Moreover, we were able to identify a few series of compounds that 
exhibit structure specific binding to iASPP.  We measured the binding affinity for many 
of these fragments and identified fragments that could be used to further develop a small 
molecule inhibitor to iASPP.  Thus, the first criterion in determining if iASPP is a 
valuable target was met.   
 
Next, we investigated whether a binding assay for iASPP could be developed. These 
assays are needed to establish whether small molecules are capable of disrupting 
biologically relevant interactions of iASPP.  Towards this end, we attempted to develop a 
FPA assay. However, we observed a protein-dependent decrease in total fluorescence in 
our assay.  In addition, we found that the binding affinity of the labeled peptide measured 
in the FPA assay was not in good agreement with the affinity of the labeled peptide 
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measured by NMR.  These data indicate that our FPA assay is not that reliable and thus 
we abandoned this assay.  It might be possible to improve this assay by using a different 
fluorophore and/or peptide or to develop an antibody-based assay. However, we were 
unable to validate iASPP as a cancer target using siRNA by experiments conducted by 
another member of our group, Bhavaratini Vangamundi, as outlined below.   
 
In order to verify and further validate the role of iASPP in cancer cells, Bhavaratini used 
siRNA to silence iASPP in select cell lines.  Seven commercial siRNA motifs 
(Dharmacon and Santa Cruz) were chosen to silence iASPP.  Four of the siRNA 
constructs resulted in greater than 90% reduction of the protein levels without a 
corresponding decrease in cancer cell growth or number. This data suggests that perhaps 
inhibiting iASPP will not have the desired effect. Other groups have reported that iASPP 
knockdown was accompanied by a selective decrease in cancer cell proliferation (Li u et 
al. 2009, Liu et al. 2004, Chen et al. 2010).  We were able to attain such results with three 
of the siRNA constructs on particular cell lines.  However, one of the constructs that was 
able to cause a decrease in cancer cell proliferation only reduced protein expression by 
approximately 80%.  These results may be explained by off target effects of the siRNA.  
Thus, we were unable to correlate protein knockdown with anti-proliferative effects using 
a number of discrete siRNA motifs against iASPP. Therefore, we did not meet our third 
criterion in our evaluation of iASPP as a valuable cancer target and decided to stop 
working on this target to purse other more promising protein targets in our lab.   
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